We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Pozen Sues Par Pharmaceutical Over Migraine ANDA

Law360 (November 17, 2008, 12:00 AM EST) -- Pozen Inc., a North Carolina-based pharmaceutical company specializing in pain medication, has sued Par Pharmaceutical Inc., for seeking regulatory approval of a generic version of Pozen's patented migraine treatment Treximet.

The complaint, filed in the U.S. District Court for the Eastern District of Texas on Friday, claims New Jersey-based Par Pharmaceutical infringed three Pozen patents when it filed an abbreviated new drug application with the U.S. Food and Drug Administration for a generic form of Treximet, which consists of 85 mg of sumatriptan and 500 mg...
To view the full article, register now.